Acorda Therapeutics Inc (ACOR): Jane Wasman , President, Intl and GC of Acorda Therapeutics Inc sold 500 shares on Sep 23, 2016. The Insider selling transaction was reported by the company on Sep 27, 2016 to the Securities and Exchange Commission. The shares were sold at $27.32 per share for a total value of $13,660.30 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 24, 2016, David Lawrence (Chief of Business Operations) sold 500 shares at $25.09 per share price.On Jun 10, 2016, Steven M Rauscher (director) sold 1,086 shares at $27.83 per share price.Also, On May 16, 2016, Andrew A. Hindman (Chief Business Dev. Officer) sold 4,860 shares at $26.11 per share price.On Apr 21, 2016, Lorin Randall (director) sold 1,488 shares at $28.68 per share price.
Acorda Therapeutics Inc: On Thursday, Sep 22, 2016 heightened volatility was witnessed in Acorda Therapeutics Inc which led to swings in the share price. The shares opened for trading at $27.06 and hit $27.26 on the upside , eventually ending the session at $27.22, with a gain of 0.55% or 0.15 points. The heightened volatility saw the trading volume jump to 6,36,552 shares. The 52-week high of the share price is $43.63 and the company has a market cap of $1,256 M . The 52-week low of the share price is at $23.59.
Acorda Therapeutics Inc. is a biopharmaceutical company engaged in the identification development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies including Ampyra (dalfampridine) Extended Release Tablets 10milligrams a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets FDA-approved as short-acting drugs for the management of spasticity and Qutenza an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders including chronic post-stroke walking deficits (PSWD) Parkinsons disease epilepsy heart failure MS and spinal cord injury.